Aganirsen, a topical antisense drug in development for treating inflammation-related corneal neovascularization (CNV), failed to reach the primary endpoint of visual acuity in a phase III trial, but its developer Gene Signal International SA plans to start a confirmatory trial later this year based on a different endpoint, having seen a significant reduction in the extent of neovascularization between the two treatment groups.